CRISPR Therapeutics (CRSP) Misses Q1 EPS by 37c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $7.1 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• ​SpaceX plans to launch new AI model with Cursor - The Information
• Citi Starts Dynapack International (3211:TT) at Buy
• JPMorgan Reiterates Underweight Rating on DSM-Firmenich AG (DSFIR:NA), Places on Negative CW